Developing a comprehensive approach to understand and treat Alzheimer's disease and related dementias.
Official title: A Multimodal, Multiscale and Multistage Systems Biology (M3SB) Infrastructure for Precision Medicine in Alzheimer’s Disease and Longevity
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11115357 · Data updated 2026-11-12
This study is working to combine different types of health information to better understand Alzheimer's and related dementias, with the hope of finding new treatments that can help slow down the disease and improve the lives of patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | June 1, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $802,034 |
| NIH project number | 1R01AG092591-01 |
| Project ID | NIH-11115357 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or related dementias, particularly those who are experiencing early to moderate stages of the disease.
✕Less likely to help
Patients with advanced Alzheimer's disease or those with other unrelated cognitive impairments may not benefit from this research.
What this research studies
This research aims to create a sophisticated infrastructure that integrates various biological data types, including genetic and real-world patient information, to better understand Alzheimer's disease (AD) and related dementias (ADRD). By utilizing a multimodal approach, the project seeks to identify key biological factors and mechanisms that contribute to these conditions. The goal is to develop targeted therapies that can modify the disease's progression and improve patient outcomes. Patients may benefit from advancements in treatment options that are informed by a deeper understanding of the underlying biology of aging and dementia.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for Alzheimer's disease and related dementias, improving the quality of life for patients.
How similar studies have gone: Previous research utilizing multimodal and systems biology approaches has shown promise in understanding complex diseases, suggesting that this innovative method could yield significant insights and advancements.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Cheng, Feixiong — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Cheng, Feixiong
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.